Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 January 2025 | Story Gerda-Marie van Rooyen | Photo Supplied
Prof Linus Franke
Leading the research in South Africa is Prof Linus Franke from the Department of Soil, Crop and Climate Sciences.

Scientists are actively pursuing the successful breeding of diploid hybrid potatoes from inbred lines. This is expected to revolutionise potato breeding as it holds the key to rapid genetic progress. It will introduce new varieties for commercialisation through seed. Currently, existing potato variants have a gene that renders self-pollinated seeds infertile.

Prof Linus Franke, an academic in the Department of Soil, Crop and Climate Sciences at the UFS, is leading the research in South Africa. “This technology allows the production of genetically uniform potato seed that is easy to transport and largely disease-free.” He says this differs from conventional breeding whereby only vegetative propagation is possible due to tetraploid varieties in potatoes. It also risks carrying pests and diseases from one generation to the next – leading to the accumulation of pests and diseases with each round of multiplication.

Seed innovation

Prof Franke explains that Solynta BV, a seed company based in the Netherlands that produces potato varieties that can be grown from seed, has included South Africa in their research efforts because it is one of Africa’s largest producers and exporters. Through his academic relationship with Wageningen University and Research, a Dutch institution renowned for its agricultural endeavours and food production, the UFS became involved in researching hybrid potatoes grown from seed.

Diploid seeds containing two sets of chromosomes allow easier gene manipulation to increase predictability and speedier genetic progress. The breeding approach enables the incorporation of tolerance to pests, diseases, abiotic stresses (cold, heat, drought) and other desired genetic traits.

Although Prof Franke is optimistic about this research, he is not blind to disadvantages. “Potato seeds are tiny and have little energy reserves, making it harder to grow potatoes from seed than from tubers.” He says potatoes from seed will take longer to cultivate than tubers, as farmers need to grow plantlets from seeds first, adding six weeks to the growing period. “It is possible that commercial farmers can grow potatoes directly from seed. Alternatively, perhaps more likely, specialised growers will produce tubers of potatoes from seed; these tubers are then sold as seed tubers to other potato farmers, who then continue their normal practices of producing potatoes for the market from tubers.”

Financial benefits

Prof Franke says farmers have reason to get excited. “Seed potatoes will reduce input costs, as varieties with enhanced tolerance to pests and diseases require less pesticides. Planting one hectare of potatoes requires three to four tonnes of potato tubers, but only one 25 g packet of potato seeds.” Since potatoes are a more valuable commodity than maize, this technology might also increase farmers’ income potential.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept